Dostarlimab-Gxly

Introduction Overview

Generic Name

dostarlimab-gxly

Brand Name

Jemperli

Dosage Form

Injection for intravenous infusion 500 mg/10 mL (50 mg/mL)

Drug Class

Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Pharmacokinetics

Absorption: Jemperli (dostarlimab-gxly) is administered intravenously, bypassing the gastrointestinal tract and systemic barriers to absorption associated with oral administration. As an intravenous infusion, dostarlimab ensures 100% bioavailability immediately upon administration, allowing for rapid systemic exposure suitable for its immunotherapeutic action. The standard infusion duration of approximately 30 minutes facilitates controlled delivery and mitigates infusion-related adverse reactions. Distribution: Following intravenous administration, dostarlimab distributes primarily within the vascular and interstitial compartments. As a large IgG4 monoclonal antibody (~150 kDa), its distribution volume is relatively limited to plasma and extracellular fluid, with minimal penetration into protected compartments such as the central nervous system due to the blood-brain barrier. Monoclonal antibodies typically exhibit limited tissue distribution but accumulate preferentially at sites of PD-1 expressing immune cells and tumor tissues, benefiting from receptor-mediated binding and tumor microenvironment targeting. Metabolism: Dostarlimab, like other monoclonal antibodies, undergoes catabolism via nonspecific pathways into small peptides and amino acids through proteolytic degradation by reticuloendothelial system cells, endothelial cells, and target-mediated endocytosis after binding PD-1 receptors. It is not a substrate for hepatic cytochrome P450 enzymes and is not metabolized via typical xenobiotic pathways, reducing the potential for hepatic metabolism-related drug interactions. The metabolism involves classical immune clearance mechanisms without formation of active or toxic metabolites. Elimination: The elimination of dostarlimab occurs predominantly via proteolytic catabolism to peptides and amino acids, with an estimated half-life in the range of approximately 20 days, consistent with IgG4 monoclonal antibodies. Clearance mechanisms include target-mediated drug disposition through binding to PD-1 receptors on lymphocytes and nonspecific proteolytic degradation in vascular and tissue compartments. Renal and hepatic elimination are not significant routes for monoclonal antibodies due to their large molecular size. Factors such as tumor burden and expression of PD-1 can influence clearance rates. The dosing schedule (500 mg every 3 weeks initially, followed by 1,000 mg every 6 weeks) reflects its sustained pharmacokinetic profile allowing for extended dosing intervals.

Dosage Forms

Available Dosage Forms: Jemperli is formulated as a single-dose vial for intravenous infusion containing 500 mg of dostarlimab-gxly in 10 mL (50 mg/mL) sterile solution. This parenteral preparation is free from preservatives and intended exclusively for intravenous administration with aseptic techniques.

Dosages for Adults and Adolescents: The recommended adult dosing regimen of Jemperli depends on the indication and combination treatment:
- For primary advanced or recurrent endometrial cancer: Jemperli 500 mg IV every 3 weeks for 6 cycles combined with carboplatin and paclitaxel, followed by 1,000 mg IV monotherapy every 6 weeks thereafter.
- For mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (single agent): 500 mg IV every 3 weeks for 4 cycles, followed by 1,000 mg IV every 6 weeks.
- For mismatch repair deficient (dMMR) recurrent or advanced solid tumors (single agent): same as above, 500 mg IV every 3 weeks for 4 cycles, then 1,000 mg every 6 weeks.

Each infusion is administered over approximately 30 minutes.

Specific Patient Populations: Dose adjustments for special populations such as pediatrics, elderly, renal or hepatic impairment have not been established due to limited clinical data. The drug is not recommended during pregnancy due to potential harm to the fetus; women of childbearing potential should use effective contraception during treatment and for 4 months after last dose. Breastfeeding is not advised for at least 4 months post-treatment. No specific dosage reduction guidelines exist for patients with organ dysfunction; clinical judgement and specialist consultation are advised. Treatment interruptions or discontinuation may be needed in severe immune-related adverse reactions.

Mechanism Of Action

Jemperli (dostarlimab-gxly) is a humanized monoclonal antibody that specifically targets programmed death receptor-1 (PD-1), a cell surface immunoinhibitory receptor expressed on activated T cells. PD-1 binds to its ligands PD-L1 and PD-L2, expressed on tumor cells and antigen-presenting cells, delivering an inhibitory signal that downregulates T-cell effector functions and promotes immune tolerance to tumors. By binding to PD-1, Jemperli blocks these interactions, thereby restoring T-cell activation and proliferation.

At the molecular level, this blockade disrupts the PD-1/PD-L1 immune checkpoint pathway, effectively reversing tumor-induced T-cell exhaustion and anergy. Activated T cells regain ability to secrete cytotoxic cytokines (e.g., IFN-γ, TNF-α) and engage in direct cytolytic activity via perforin and granzyme release, leading to enhanced tumor cell apoptosis and immune-mediated tumor clearance. This mechanism enables the immune system to recognize and destroy cancer cells that have otherwise evaded immune surveillance.

Unlike cytotoxic chemotherapies that directly kill tumor cells, Jemperli's immunomodulatory mechanism enhances endogenous anti-tumor immunity with the potential for durable clinical responses. It leverages cancer immunoediting principles targeting the adaptive immune checkpoints. Compared to other anti-PD-1 agents such as pembrolizumab or nivolumab, dostarlimab shares a similar binding domain and blockade effect but may differ subtly in epitope affinity and pharmacokinetic profiles.

Clinical studies demonstrate Jemperli's efficacy in mismatch repair deficient (dMMR) tumors, highlighting the predictive biomarker role of DNA repair deficiency for increased neoantigen load and subsequent greater immune responsiveness. This immunotherapeutic approach represents a paradigm shift in oncology, converting non-responsive tumor microenvironments into immunologically active niches through checkpoint inhibition.

Pharmacological Actions

Blocks programmed death receptor-1 (PD-1) checkpoint, reversing T-cell inhibition.
Enhances T-cell activation, proliferation, and cytotoxic function against tumor cells.
Promotes immune-mediated tumor cell apoptosis via restored immune surveillance.
Targets immunosuppressive tumor microenvironment to enable durable anti-tumor immunity.
Modulates adaptive immune response without directly killing tumor cells.
Inhibits binding of PD-1 to its ligands PD-L1 and PD-L2, key immune checkpoint proteins.
Induces long-lasting immune memory potentially reducing tumor recurrence.
Effective particularly in tumors with mismatch repair deficiency (dMMR) due to increased neoantigens.
Synergistic when combined with chemotherapeutic agents such as carboplatin and paclitaxel.
Minimal direct toxicity to non-immune normal tissues via selective checkpoint blockade.
Augments cytokine secretion and recruitment of effector T cells in tumor milieu.
Stimulation of immune response may lead to inflammatory adverse events in normal tissues.

Therapeutic Or Clinical Uses

Treatment of primary advanced or recurrent endometrial cancer in combination with carboplatin and paclitaxel, followed by maintenance monotherapy.
Monotherapy for mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer following progression on platinum-containing regimens.
Monotherapy for mismatch repair deficient (dMMR) recurrent or advanced solid tumors after progression and when no satisfactory alternatives exist.
Immunotherapy for adult patients with cancers demonstrating defective DNA mismatch repair status.
Used as part of combination cancer regimens to enhance overall response rates in endometrial cancer.
Management option for patients ineligible for curative surgery or radiation for endometrial cancer.
Treatment option for heavily pretreated solid tumors with limited therapeutic alternatives.
Offers novel mechanism for tumors expressing PD-1 ligands with immune evasion properties.
Potential use in various solid tumors pending biomarker and clinical data confirmation.
Extended dosing intervals improve patient compliance during long-term maintenance therapy.

Side Or Adverse Effects

Fatigue and weakness, commonly reported in monotherapy settings.
Anemia characterized by low red blood cell counts.
Gastrointestinal symptoms including diarrhea, nausea, vomiting, and constipation.
Peripheral neuropathy symptoms including nerve problems in extremities when combined with chemotherapy.
Joint pain and musculoskeletal discomfort.
Respiratory complaints such as shortness of breath and pneumonitis.
Rash and skin-related adverse events including itching and possible severe skin reactions.
Decreased appetite and unintended weight changes.
Urinary tract infections among patients receiving combination therapy.
Hair loss (alopecia) and abdominal pain reported in combination regimens.
Potential for severe immune-mediated adverse reactions affecting lung, liver, colon, kidneys, endocrine glands, and skin.
Infusion-related reactions including chills, fever, rash, flushing, and hypotension during administration.
Life-threatening immune system attacks on healthy tissues leading to organ dysfunction.
Allergic reactions such as anaphylaxis, facial swelling, and difficulty breathing.
Possible graft-versus-host disease complications in patients with prior allogeneic stem cell transplants.

Precautions

Monitor for immune-related adverse events affecting lungs, intestines, liver, kidneys, endocrine glands, and skin.
Schedule regular laboratory tests to detect early signs of organ dysfunction during treatment.
Avoid use in patients with active autoimmune diseases unless benefits outweigh risks.
Cautiously use in patients with prior organ transplantation due to risk of graft rejection.
Discontinue therapy for severe or life-threatening immune-mediated side effects.
Pregnancy testing recommended prior to initiation; advise effective contraception during therapy and 4 months after last dose.
Breastfeeding is contraindicated during therapy and for 4 months post-treatment due to unknown excretion in milk.
Be vigilant for signs of infusion reactions; premedication may be considered in at-risk patients.
Adjust dosing regimen or withhold treatment based on severity of adverse events and clinical judgment.
Educate patients about symptoms of immune-related toxicities and importance of timely reporting.
Avoid live vaccines during and after treatment until immune system recovery.
Use caution in patients with pre-existing lung or inflammatory bowel diseases.
Screen for hormone gland dysfunctions regularly including adrenal, thyroid, pituitary, and pancreatic functions.
Assess neurologic status in patients with prior neurologic conditions such as myasthenia gravis.

Warnings

Potential for severe, life-threatening immune-mediated adverse reactions affecting multiple organs.
Risk of infusion reactions, some of which may require emergency intervention.
May cause immune system attacks on normal tissues leading to pneumonitis, colitis, hepatitis, nephritis, endocrinopathies, and dermatologic toxicities.
Can cause fetal harm; contraindicated in pregnancy without extreme necessity.
Possibility of graft rejection in patients with previous organ transplants.
Potential for severe graft-versus-host disease in patients with prior allogeneic bone marrow transplants.
Treatment interruptions or permanent discontinuation may be necessary for severe toxicities.
Use with caution when combined with chemotherapeutic agents due to overlapping toxicities.
Close monitoring advised for patients with pre-existing autoimmune or inflammatory conditions.
Delayed onset of adverse events can occur; vigilance required even after treatment cessation.
Impaired wound healing potential due to immune modulation.
Risk of infection may be increased secondary to immune dysregulation.
Adequate supportive care and corticosteroid therapy should be instituted promptly for immune toxicities.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Inadequate data on long-term safety and carcinogenicity; monitor patients accordingly.

Contraindication

Known hypersensitivity to dostarlimab-gxly or any component of the formulation.
Active, severe autoimmune diseases requiring systemic treatment within the past 2 years.
Recipients of allogeneic organ transplants due to potential for graft rejection.
Use during pregnancy unless the potential benefit justifies the risk to the fetus.
Breastfeeding during therapy and for at least 4 months following last dose.
Use in pediatric patients due to insufficient safety data.
Coadministration with other immunotherapeutics that may increase risk of immune-related adverse events without careful monitoring.
Patients with a history of severe infusion reactions to similar monoclonal antibodies unless appropriate management plans are in place.
Concurrent use with live attenuated vaccines.
Patients with uncontrolled intercurrent illnesses or infections that may be exacerbated by immunotherapy.

Drug Interactions

Potential interaction with immunosuppressive agents that may antagonize the therapeutic effect of Jemperli.
Caution when combined with chemotherapy agents such as carboplatin and paclitaxel due to additive toxicities.
No significant CYP450-mediated drug-drug interactions as monoclonal antibodies are not metabolized by hepatic enzymes.
Use with systemic corticosteroids may diminish immunotherapeutic effectiveness unless used for managing immune-related adverse events.
Vaccinations with live vaccines should be avoided during and after Jemperli treatment.
Limited data on interactions with other biologics; potential for enhanced immunosuppression or toxicity.
Concurrent use with agents that affect immune checkpoint pathways could result in unpredictable immune modulation.
No known interactions with common supportive care medications such as antiemetics or pain medications.
Drugs that affect renal or hepatic function unlikely to impact Jemperli pharmacokinetics significantly.
Potential for increased severity of infusion reactions when administered with other immune-stimulating agents.
Interactions with herbal supplements affecting the immune system have not been well studied.
Avoid concomitant use with other immune checkpoint inhibitors without clinical justification.
Patients should inform healthcare providers about all medications to evaluate potential immune-modulatory interactions.

Preparations Of The Drug

Active ingredient: dostarlimab-gxly, a humanized IgG4 monoclonal antibody targeting PD-1.
Provided as a sterile, clear, colorless to slightly yellow solution for intravenous infusion.
Formulated at a concentration of 50 mg/mL in 10 mL single-dose vials containing 500 mg per vial.
Inactive ingredients include citric acid monohydrate, L-arginine hydrochloride, polysorbate 80, sodium chloride, trisodium citrate dihydrate, and Water for Injection.
Supplied in preservative-free form requiring aseptic technique for dilution and administration.
Storage conditions: store refrigerated at 2°C to 8°C (36°F to 46°F), do not freeze, protect from light.
Vials intended for single use only; discard any unused portion per institutional policies.
Requires dilution and infusion via intravenous line using sterile, non-pyrogenic equipment compatible with monoclonal antibodies.
Prepared by healthcare professionals trained in handling biologic agents to prevent contamination and maintain stability.
Label includes black box warning regarding immune-mediated side effects and instructions for emergency response.
Manufacturer: GlaxoSmithKline LLC, Philadelphia, PA, USA.
Distributed by GlaxoSmithKline, Durham, NC, USA.
Packaging includes detailed patient and healthcare provider information leaflets outlining administration, monitoring, and side effect management.